Invasive NSTEMI Strategy Shows No Benefit in Frail Patients

Frailty severity may identify older patients least likely to benefit—and potentially at higher risk—with invasive management.

1

A routine invasive strategy did not reduce cardiovascular death or nonfatal myocardial infarction in frail patients aged 75 and older with NSTEMI.
2

Invasive management showed a hazard ratio of 1.21 for the primary outcome among frail patients, indicating worse outcomes compared to conservative care.
3

The study found no significant benefits of invasive strategies in frail patients, contrasting with the overall SENIOR-RITA trial population.
4

Higher frailty levels correlated with increased relative disadvantage from invasive management, suggesting potential harm in this subgroup.
5

The findings emphasize the need to assess frailty severity when making treatment decisions for older patients with non-ST-elevation myocardial infarction.

1